期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 111, 期 48, 页码 17104-17109出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1418637111
关键词
cancer metastasis; nanotechnology; diagnostic; mRNA; NanoFlares
资金
- National Cancer Institute through the Center for Cancer Nanotechnology Excellence initiative of the NIH [U54CA151880]
- Howard Hughes Medical Institute for a Physician Scientist Early Career Award
- Air Force Office of Scientific Research Grant [FA95501310192]
- National Cancer Institute Grant [R01CA167041]
- American Cancer Society [RSG-09-252-01-RMC]
- NIH [R01 CA182467]
- Ryan family
- Malkin family
- Department of Defense through the National Defense Science and Engineering Graduate fellowship
Metastasis portends a poor prognosis for cancer patients. Primary tumor cells disseminate through the bloodstream before the appearance of detectable metastatic lesions. The analysis of cancer cells in blood-so-called circulating tumor cells (CTCs)-may provide unprecedented opportunities for metastatic risk assessment and investigation. NanoFlares are nanoconstructs that enable livecell detection of intracellular mRNA. NanoFlares, when coupled with flow cytometry, can be used to fluorescently detect genetic markers of CTCs in the context of whole blood. They allow one to detect as few as 100 live cancer cells per mL of blood and subsequently culture those cells. This technique can also be used to detect CTCs in a murine model of metastatic breast cancer. As such, NanoFlares provide, to our knowledge, the first genetic-based approach for detecting, isolating, and characterizing live cancer cells from blood and may provide new opportunities for cancer diagnosis, prognosis, and personalized therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据